RG 101

Drug Profile

RG 101

Alternative Names: RG-101; RG-101Rx

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Regulus Therapeutics
  • Class Antisense oligonucleotides; Antivirals; MicroRNAs
  • Mechanism of Action MIRN122 microRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Aug 2017 Discontinued - Phase-I for Hepatitis C in USA, Netherlands (SC) before August 2017
  • 01 Aug 2017 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Spain, Greece, Hungary (SC) before August 2017
  • 12 Jun 2017 Regulus Therapeutics intends to discontinue development of RG 101 in Hepatitis C in July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top